769 |
LEADERS: Analysis of 9 Months OCT Results |
Patrick W. Serruys |
Jul. 22. 09 |
768 |
Assessment of LEADERS 12 Months Result |
Patrick W. Serruys |
Jul. 22. 09 |
767 |
AMI Intervention in DES Era and Beyond |
Harry Suryapranata |
Jul. 22. 09 |
766 |
Genous Stent in Real-World Experience and TRIAS HR Pilot Study Long Term Follow Up |
Margo Klomp |
Jul. 22. 09 |
765 |
Development of a Novel Sirolimus Eluting Pro-Healing Stent |
Juan F. Granada |
Jul. 22. 09 |
764 |
The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses |
David Joel Cohen |
Jul. 22. 09 |
763 |
Medical Statistics 101: Basic Comparative Statistics, Parametric and Non Parametric P Values and Confidence Intervals, Trial Size |
Donald E. Cutlip |
Jul. 22. 09 |
762 |
Regulatory Perspectives Of Clinical Trials: What Core Elements does FDA Look for? |
Heather Agler |
Jul. 22. 09 |
761 |
Responsibilities of Investigators in Clinical Trials: From Consent to Safety Reporting |
Young-Hak Kim |
Jul. 22. 09 |
760 |
Quality Control of Clinical Trials: Blinding, Clinical Event Committees, Core Labs, and Data Standards |
Roxana Mehran |
Jul. 22. 09 |